IL-17 A Inhibitor Switching – Efficacy of Ixekizumab Following Secukinumab Failure . A Single-center Experience

[1]  G. Pellacani,et al.  Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience , 2019, The British journal of dermatology.

[2]  D. Vidal,et al.  Initial results of ixekizumab efficacy and safety in real‐world plaque psoriasis patients: a multicentre retrospective study , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  V. Bini,et al.  Efficacy and safety of adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behavior in real life clinical practice , 2018, The Journal of dermatological treatment.

[4]  Therezia Bokor-Billmann,et al.  No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis , 2018, The Journal of dermatological treatment.

[5]  J. Yeung,et al.  Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies , 2018, Journal of the American Academy of Dermatology.

[6]  R. Warren,et al.  Matching‐adjusted indirect comparison of efficacy in patients with moderate‐to‐severe plaque psoriasis treated with ixekizumab vs. secukinumab , 2018, The British journal of dermatology.

[7]  E. Hodak,et al.  Can etanercept treatment failure in moderate-to-severe psoriasis be overcome by addition of low-dose methotrexate? A single-center experience , 2018, The Journal of dermatological treatment.

[8]  L. Skov,et al.  Safety, efficacy and drug survival of biologics and biosimilars for moderate‐to‐severe plaque psoriasis , 2018, The British journal of dermatology.

[9]  T. Luger,et al.  Secukinumab sustains good efficacy and favourable safety in moderate‐to‐severe psoriasis after up to 3 years of treatment: results from a double‐blind extension study , 2017, The British journal of dermatology.

[10]  I. Feldhamer,et al.  Biologic drug survival in Israeli psoriasis patients , 2017, Journal of the American Academy of Dermatology.

[11]  J. Doshi,et al.  Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. , 2016, Journal of the American Academy of Dermatology.

[12]  F. Vanaclocha,et al.  Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. , 2015, Journal of the American Academy of Dermatology.

[13]  F. Kerdel,et al.  An evolution in switching therapy for psoriasis patients who fail to meet treatment goals , 2015, Dermatologic therapy.

[14]  M. Lebwohl,et al.  Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials , 2015, The Lancet.

[15]  C. Lereun,et al.  Comparative efficacy of biological treatments for moderate‐to‐severe psoriasis: a network meta‐analysis adjusting for cross‐trial differences in reference arm response , 2015, The British journal of dermatology.

[16]  B. Elewski,et al.  Secukinumab in plaque psoriasis--results of two phase 3 trials. , 2014, The New England journal of medicine.

[17]  M. Lebwohl,et al.  Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. , 2014, Journal of the American Academy of Dermatology.

[18]  L. Naldi,et al.  Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry. , 2014, Journal of the American Academy of Dermatology.

[19]  B. Strober,et al.  Consensus guidelines for the management of plaque psoriasis. , 2012, Archives of dermatology.

[20]  S. Chimenti,et al.  Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti‐tumour necrosis factor agents: subanalysis of BELIEVE , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

[21]  B. Strober,et al.  Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. , 2011, Journal of the American Academy of Dermatology.

[22]  J. Koo,et al.  Paradoxical worsening of psoriasis when switching from etanercept to adalimumab: A case series , 2011, The Journal of dermatological treatment.

[23]  P. V. D. van de Kerkhof,et al.  Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept , 2010, The British journal of dermatology.

[24]  R. Bissonnette,et al.  Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept. , 2010, Journal of the American Academy of Dermatology.